Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alternative Treatment Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Bone Response to Soy Isoflavones in Women

NCT00043745
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Soy isoflavones, Extract tablets
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Davis, California • Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoolSculpting of the Flank With Alternate Treatment Parameters

NCT02081196
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq CoolSculpting System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Sacramento, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
View directory record Official record
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Alternative Dosing Schedule of Varenicline for Smoking Cessation

NCT00835900
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline, placebo
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss

NCT07627971
View directory record Official record
Conditions
GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
Interventions
SKY-GJB2
Combination Product
Lead sponsor
Skylark Bio Inc.
Industry
Eligibility
9 Months to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

NCT00273364
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Alternative Therapy for Improving Cognition, Balance, and Physical Activity

NCT04160299
View directory record Official record
Conditions
Mild Cognitive Impairment, Older Adults, Neurological Injury
Interventions
Dance-based exergaming
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
65 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

NCT03583164
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
Olorofim
Drug
Lead sponsor
F2G Biotech GmbH
Industry
Eligibility
16 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Bakersfield, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 20, 2026, 4:09 PM EDT
Terminated Phase 4 Interventional Results available

Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy

NCT04594070
View directory record Official record
Conditions
Pregnancy Related, Iron Deficiency Anemia of Pregnancy
Interventions
Ferrous sulfate
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 3 Interventional

Alternative Stress Management Approaches in HIV Disease

NCT00029237
View directory record Official record
Conditions
HIV Infections
Interventions
Cognitive-behavioral relaxation (Positively Living), Spiritual growth group, Focused Tai Chi
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 20, 2026, 4:09 PM EDT
Not listed Phase 2 Interventional Results available

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945
View directory record Official record
Conditions
BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cetuximab, Irinotecan, Panitumumab, Regorafenib
Biological · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 20, 2026, 4:09 PM EDT
Recruiting Phase 3 Interventional

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

NCT07100782
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Relugolix CT
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Alternative Treatments for Premenstrual Dysphoric Disorder

NCT01799733
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder
Interventions
LWT+AM BWL, EWT+PM BWL
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 20, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional

Low Field Magnetic Stimulation Treatment for Bipolar Depression

NCT00217217
View directory record Official record
Conditions
Bipolar Depression, Bipolar Disorder, Depression
Interventions
Echo-Planar Magnetic Resonance Imaging (EP-MRSI)
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 20, 2026, 4:09 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

NCT04584255
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
8
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 4 Interventional

Alternative Dosing Strategy for Anti-HIV Drugs

NCT00059384
View directory record Official record
Conditions
HIV Infections
Interventions
Concentration-controlled therapy
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2008 · Synced Oct 20, 2026, 4:09 PM EDT
Not yet recruiting Phase 1 Interventional

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

NCT07511062
View directory record Official record
Conditions
Acute Myeloid Leukemia, TP53 Gene Mutation
Interventions
Decitabine, Venetoclax, Axatilimab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Q-Trial in Patients With Hepatitis C

NCT01438320
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Quercetin
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

NCT03285802
View directory record Official record
Conditions
Uterine Cancer
Interventions
Letrozole, Everolimus
Drug
Lead sponsor
Greater Baltimore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 2Phase 3 Interventional

Meditation-Based Treatment for Binge Eating Disorder

NCT00032760
View directory record Official record
Conditions
Binge Eating Disorder, Obesity
Interventions
Meditation
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Terre Haute, Indiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 20, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

NCT01531361
View directory record Official record
Conditions
Advanced Malignant Neoplasm, BRAF Gene Mutation, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Vemurafenib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 20, 2026, 4:09 PM EDT
Terminated Phase 4 Interventional

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

NCT05183828
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
Interventions
Biospecimen Collection, Letrozole, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 4:09 PM EDT